6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Earl, Helena; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes‐Davies, Luke; Harnett, Adrian; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen; Wilcox, Maggie; Plummer, Chris; Mansi, Janine; Gounaris, Ioannis; Mahler‐Araujo, Betania; Provenzano, Elena; Chhabra, Anita; Abraham, Jean; Caldas, Carlos; S Hall, Peter; McCabe, Christopher; Hulme, Claire; Miles, David; Wardley, Andrew; Cameron, David; Dunn, Janet; Agarwal, Roshan; Algurafi, Hafiz; Allerton, R.; Archer, Caroline; Armstrong, Anne; Bale, C.; Barraclough, Lisa; Barthakur, U.; Bedi, C.; Benstead, Kim; Bloomfield, David; Bowen, Rebecca; Bradley, Chris; Brown, Jane; Butt, Mohammad; Churn, Mark; Cleator, Susan; Cliff, Joanne; Crellin, Perric; Daly, Margaret; De Silva-Minor, Shiroma; Dhadda, A.S.; Din, Omar; Down, Sue; Earl, Helena; Eaton, David; Eichholz, Andrew; Epurescu, Daniel; Goh, Chee; Goodman, Andrew; Grieve, Robert; Hadaki, Maher; Harper‐Wynne, Catherine; Harries, Mark; Hayward, Larry; Humphreys, Alison; Innes, Helen; Jafri, Mariam; Jegannathen, A.; Kelleher, Muireann; Kristeleit, Hartmut; Lee, Daniela; Lupton, Susan; MacGregor, Carol; Malik, Zafar; Mansi, Janine; Marshall, Jennifer; McAdam, Karen; McGolick, Trevor; Mehra, Rakesh; Miles, David; Mithal, Natasha; Moss, Charlotte; Moss, Aian; Mukesh, Mukesh; Neal, Anthony; Nelmes, D.; Neville-Webbe, Helen; C. Newby, Jacqueline; O'Reilly, Susan; Ostler, Peter; Persic, Mojca; Pettit, Laura; Raj, Sanjay; Raja, Fharat; Rea, Daniel; Reed, Catherine; Rigg, Anne; Roe, Helen; Shah, Nihal; Simmonds, Peter; Sims, Eliot; Smith, Sarah; Storey, Nicola; Chris Taylor, W.; Thanvi, Narottam; Tipples, Karen; S. Vaidya, Jayant; Varughese, Mohini; Vinayan, Anup; Walji, Nawaz; Waters, Simon; Woodings, Pamela; Wright, Kathryn; Yahya, Sundus

doi:10.1016/s0140-6736(19)30650-6

Public

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Published in The Lancet • Jun 1, 2019

Authors:

Helena Earl

Louise Hiller

Anne-Laure Vallier

Abstract

BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant...

Subject

Medicine

Trastuzumab

Breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!